NOD-like Receptor (NLR) Modulator

Usnoflast is the selective, orally active inhibitor for NLRP3 that blocks the release of IL-1β, and exhibits anti-inflammatory activity.

L18I is a Bruton's tyrosine kinase (BTK) PROTAC degrader that targets wild-type and BTK^C481, and recruits the cereblon E3 ligase to mediate proteasomal degradation. L18I regulates the BCR, TLR, FcγR and NLRP3 inflammasome signaling pathways, inhibits the phosphorylation of PLCγ-2, ERK1/2 and p38, and reduces the levels of B cell activation markers CD25, CD69 and CD86. L18I downregulates the NF-κB, TNF and TLR signaling pathways, reduces the production of pro-inflammatory cytokines, and decreases immune cell infiltration and immune complex deposition. L18I inhibits the proliferation of BTK-expressing lymphoma cells, induces tumor regression in xenograft models, and exhibits synergistic activity when combined with inhibitors of SYK, PI3K or Lyn. L18I can be used in research related to lupus, diffuse alveolar hemorrhage and B-cell lymphoma.

NLRP3 modulator 7 (Compound 17B) is a NLRP3 inflammasome modulator. NLRP3 modulator 7 inhibits LPS (HY-D1056)-induced IL-1β release in fresh human whole blood. NLRP3 modulator 7 can be used in studies related to NLRP3 inflammasome activation and innate immune signaling.

Benzylurea is an anti-inflammatory agent. Benzylurea inhibits LPS (HY-D1056)-induced upregulation of MTCH2 expression and regulates pathways associated with mitochondrial function, inflammation and cell survival. Benzylurea alleviates LPS-induced proliferation inhibition and apoptosis of periodontal ligament fibroblasts, as well as the release of proinflammatory cytokines. Benzylurea can be used in studies related to periodontitis.

NLRP3 modulator 1 is the potent modulator of NLRP3. NLRP3 modulator 1 agonizes or partially agonizes NLRP3 that are useful for researching a condition, disease or disorder in which a decrease in LRP3 activity contributes to the pathology (extracted from patent WO2017184746A1, compound 107).

Abdenoflast (Compound 12) is an NLRP3 modulator with an IL-1β inhibitory IC₅₀ < 1 μM in human whole blood.

(6Z,9Z,12Z,15Z,18Z,21Z)-Tetracosahexaenoyl-CoA ((6Z,9Z,12Z,15Z,18Z,21Z)-Tetracosahexaenoyl-coenzyme A) is a NLRX1 modulator. (6Z,9Z,12Z,15Z,18Z,21Z)-Tetracosahexaenoyl-CoA is promising for research of immune and metabolic related diseases.

Benzylurea (Standard) is the analytical standard of Benzylurea (HY-W010253). This product is intended for research and analytical applications. Benzylurea is a benzylamide. Benzylurea is an anti-inflammatory agent. Benzylurea inhibits LPS (HY-D1056)-induced upregulation of MTCH2 expression and regulates pathways associated with mitochondrial function, inflammation and cell survival. Benzylurea alleviates LPS-induced proliferation inhibition and apoptosis of periodontal ligament fibroblasts, as well as the release of proinflammatory cytokines. Benzylurea can be used in studies related to periodontitis.